Insider Buying: Precision BioSciences, Inc. (NASDAQ:DTIL) Director Buys 3,016 Shares of Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) Director Melinda Brown acquired 3,016 shares of the stock in a transaction that occurred on Thursday, December 26th. The shares were bought at an average price of $4.55 per share, for a total transaction of $13,722.80. Following the transaction, the director now owns 7,218 shares of the company’s stock, valued at $32,841.90. This trade represents a 71.78 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Precision BioSciences Price Performance

NASDAQ DTIL opened at $3.81 on Thursday. The stock has a market capitalization of $29.23 million, a price-to-earnings ratio of 63.51 and a beta of 1.41. Precision BioSciences, Inc. has a 1-year low of $3.61 and a 1-year high of $19.43. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22. The business’s fifty day moving average price is $6.59 and its 200-day moving average price is $8.51.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Precision BioSciences stock. Geode Capital Management LLC grew its holdings in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 40.7% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 65,974 shares of the company’s stock after purchasing an additional 19,088 shares during the quarter. Geode Capital Management LLC owned approximately 0.86% of Precision BioSciences worth $591,000 as of its most recent filing with the Securities & Exchange Commission. 37.99% of the stock is owned by institutional investors and hedge funds.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.